Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Raised by Concentric Wealth Management LLC

Concentric Wealth Management LLC increased its position in Bristol-Myers Squibb (NYSE:BMY) by 7.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,695 shares of the biopharmaceutical company’s stock after purchasing an additional 3,605 shares during the period. Concentric Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $2,830,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Caxton Associates LP grew its holdings in shares of Bristol-Myers Squibb by 5.5% during the first quarter. Caxton Associates LP now owns 27,369 shares of the biopharmaceutical company’s stock valued at $1,484,000 after purchasing an additional 1,430 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter worth $2,588,000. Dynasty Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter valued at about $1,265,000. Ancora Advisors LLC grew its position in Bristol-Myers Squibb by 9.8% in the 1st quarter. Ancora Advisors LLC now owns 40,938 shares of the biopharmaceutical company’s stock valued at $2,220,000 after buying an additional 3,654 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 13.7% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 185,863 shares of the biopharmaceutical company’s stock worth $10,787,000 after buying an additional 22,462 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 1.1 %

BMY opened at $58.87 on Monday. The stock has a 50-day moving average of $53.66 and a 200-day moving average of $47.77. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. During the same quarter last year, the company posted $2.00 earnings per share. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.08%. Bristol-Myers Squibb’s payout ratio is presently -66.85%.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Morgan Stanley upped their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $55.00 to $73.00 in a report on Tuesday, November 12th. Finally, Sanford C. Bernstein started coverage on Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.